Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00886782
Other study ID # CA198-002
Secondary ID EUDRACT Number:
Status Terminated
Phase Phase 1/Phase 2
First received
Last updated
Start date May 31, 2009
Est. completion date August 4, 2010

Study information

Verified date April 2023
Source Bristol-Myers Squibb
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine safety, tolerability and maximum tolerated dose of BMS-863233 in subjects advanced and/or Metastatic solid tumors.


Recruitment information / eligibility

Status Terminated
Enrollment 11
Est. completion date August 4, 2010
Est. primary completion date August 4, 2010
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Phase 1 Inclusion Criteria: - Subjects with advanced and/or metastatic solid tumors who are either refractory to or have relapsed from standard therapies, or for whom a standard therapy does not exist. - ECOG performance status = 2 - Accessible for treatment, PK sample collection and required study follow-up - Total Bilirubin = 1.5 x ULN and ALT, AST = 2.5 x ULN Exclusion Criteria: - Women who are pregnant or breastfeeding - Subjects with known or suspected brain metastasis, primary brain tumors, or brain as the only site of disease - Exposure to any investigational agent within 4 weeks of study drug administration - Subjects a history of gastrointestinal disease

Study Design


Intervention

Drug:
Cdc7-inhibitor
Capsules, Oral, QD x 14 days until MTD is reached, 14d per 28 day cycle/QD 12 months

Locations

Country Name City State
Canada Local Institution Toronto Ontario
Canada Local Institution - 003 Toronto Ontario
France Local Institution Villejuif Cedex
United States Dana-Farber Cancer Institute Boston Massachusetts
United States Dana-Farber Cancer Institute-Vendor Boston Massachusetts
United States Karmanos Cancer Institute Detroit Michigan

Sponsors (2)

Lead Sponsor Collaborator
Bristol-Myers Squibb Exelixis

Countries where clinical trial is conducted

United States,  Canada,  France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Dose Limiting Toxicities (DLTs) of BMS-863233 DLT is defined based on adverse events that are deemed to be drug-related and occur during the first cycle of therapy using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0. Up to 28 days
Primary Number of Participants With Adverse Events (AEs) Number of participants with any grade adverse events (AEs), any grade drug-related AEs, any grade serious adverse events (SAEs), any grade drug-related SAEs, and any grade AEs leading to discontinuation of any drug. The severity of AEs will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0. An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. From first dose to 30 days post last dose (Up to 14 months)
Primary Number of Participants Who Died Number of participants who died due to any cause. From first dose to 30 days post last dose (Up to 14 months)
Primary Number of Participants With Lab Abnormalities Grade 3-4 Number of participants with lab abnormalities grade 3-4 including hematology, chemistry, coagulation, liver and kidney function, and electrolytes using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0.
Grade 3 = severe Grade 4 = very severe
From first dose to 30 days post last dose (Up to 14 months)
Secondary BMS-863233 Maximum Observed Plasma Concentration (Cmax) BMS-863233 maximum observed plasma concentration (Cmax) is derived from plasma concentration versus time data. Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. PK assessment include the following timepoints: predose, 0.5-, 1-, 2-, 4-, 5-, 6-, 8-hours end-of-infusion on Cycle 1 Day 1, Cycle 1 Day 14
Secondary BMS-863233 Time of Maximum Observed Plasma Concentration (Tmax) BMS-863233 time of maximum observed plasma concentration (Tmax) is derived from plasma concentration versus time data. PK assessment include the following timepoints: predose, 0.5-, 1-, 2-, 4-, 5-, 6-, 8-hours end-of-infusion on Cycle 1 Day 1, Cycle 1 Day 14
Secondary BMS-863233 Area Under the Concentration-time Curve in One Dosing Interval (AUC(TAU)) BMS-863233 Area under the concentration-time curve in one dosing interval (AUC(TAU)) is derived from plasma concentration versus time data. Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. PK assessment include the following timepoints: predose, 0.5-, 1-, 2-, 4-, 5-, 6-, 8-hours end-of-infusion on Cycle 1 Day 1, Cycle 1 Day 14
Secondary BMS-863233 Clearance (CL) BMS-863233 clearance (CL) is derived from plasma concentration versus time data. Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. PK assessment include the following timepoints: predose, 0.5-, 1-, 2-, 4-, 5-, 6-, 8-hours end-of-infusion on Cycle 1 Day 1, Cycle 1 Day 14
Secondary BMS-863233 Effective Elimination Half-Life (T-HALFeff) Effective elimination half-life (T-HALFeff) is derived from plasma concentration versus time data. PK assessment include the following timepoints: predose, 0.5-, 1-, 2-, 4-, 5-, 6-, 8-, 36-hours end-of-infusion on Cycle 1 Day 1, Cycle 1 Day 14
Secondary BMS-863233 Accumulation Index (AI_AUC) BMS-863233 accumulation index (AI_AUC) is derived from plasma concentration versus time data. AI is calculated based on ratio of AUC(TAU) at steady state to AUC(TAU) after the first dose. Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. PK assessment include the following timepoints: predose, 0.5-, 1-, 2-, 4-, 5-, 6-, 8-hours end-of-infusion on Cycle 1 Day 1, Cycle 1 Day 14
Secondary BMS-863233 Trough Observed Plasma Concentration (Ctrough) BMS-863233 trough observed plasma concentration (Ctrough) is derived from plasma concentration versus time data. Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. PK assessment include the following timepoints: predose, 0.5-, 1-, 2-, 4-, 5-, 6-, 8-, 24-hours end-of-infusion on Cycle 1 Day 2 (C1D2), (C1D7, or D8, or D9), and C1D14
Secondary Change From Baseline in Electrocardiogram (ECG) Parameters: Mean Heart Rate Baseline = Last non-missing result with a collection date-time less than the date-time of the first active dose of study medication. Baseline and Predose, 2-, 4-, 8-, and 24-hours post dose on Cycle 1 Day 1 (C1D1), C3D1, C4D1, C1D2, C1D15, C3D15,
Secondary Change From Baseline in Electrocardiogram (ECG) Parameters: PR Interval Baseline = Last non-missing result with a collection date-time less than the date-time of the first active dose of study medication. Baseline and Predose, 2-, 4-, 8-, and 24-hours post dose on Cycle 1 Day 1 (C1D1), C1D14, C3D1, C3D15, C4D1
Secondary Change From Baseline in Electrocardiogram (ECG) Parameters: QRS Interval Baseline = Last non-missing result with a collection date-time less than the date-time of the first active dose of study medication. Baseline and Predose, 2-, 4-, 8-, and 24-hours post dose on Cycle 1 Day 1 (C1D1), C1D14, C3D1, C3D15, C4D1
Secondary Change From Baseline in Electrocardiogram (ECG) Parameters: QTcF Interval Baseline = Last non-missing result with a collection date-time less than the date-time of the first active dose of study medication. Baseline and Predose, 2-, 4-, 8-, and 24-hours post dose on Cycle 1 Day 1 (C1D1), C1D14, C3D1, C3D15, C4D1
Secondary Objective Response Rate (ORR) ORR is defined as the total percentage of participants whose best response is either a complete response (CR) or a partial response (PR) defined by the RECIST criteria.
CR= Complete disappearance of all tumor lesions. PR= Decrease, relative to baseline, of 30% or greater in the sum of the longest diameter of all "target" lesions.
From first dose up to 14 months
Secondary Disease Control Rate (DCR) DCR is defined as the total percentage of participants whose best response is complete response (CR), partial response (PR), or = 4 months stable disease (SD) defined by the RECIST criteria.
CR= Complete disappearance of all tumor lesions. PR= Decrease, relative to baseline, of 30% or greater in the sum of the longest diameter of all "target" lesions.
SD= Failure to meet criteria for complete or partial response, in the absence of progressive disease.
From first dose up to 14 months
See also
  Status Clinical Trial Phase
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Recruiting NCT05798611 - Study of ART0380 in Patients With Biologically Selected Solid Tumors Phase 2
Not yet recruiting NCT04931420 - Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels Phase 2
Recruiting NCT05566574 - A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer Phase 1/Phase 2
Recruiting NCT05036681 - A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma Phase 2
Withdrawn NCT00005030 - SCH 66336 Before Surgery in Treating Patients With Colorectal Cancer That Has Metastasized to the Liver Phase 1
Recruiting NCT05525858 - KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
Recruiting NCT04085029 - Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry
Recruiting NCT06058988 - Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer Phase 2
Not yet recruiting NCT05981170 - Rurality Adapted Physical Activity Sport Health
Not yet recruiting NCT03058809 - Evaluation of Viatarâ„¢ Oncopheresis System in Removing CTC From Whole Blood Phase 1/Phase 2
Completed NCT02529553 - A Study of LY3076226 in Participants With Advanced or Metastatic Cancer Phase 1
Terminated NCT01929941 - An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies Phase 1
Terminated NCT00918645 - Calcium-41 (41Ca) Chloride Aqueous Solution in Diagnosing Patients With Prostate Cancer and Bone Metastasis N/A
Completed NCT01302808 - Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Phase 1
Withdrawn NCT00769990 - Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases Phase 1/Phase 2
Completed NCT00795678 - Chemotherapeutic Agents in Brain/Breast N/A
Completed NCT00557102 - Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or Lung Phase 2
Recruiting NCT00398437 - Magnetic Resonance Imaging for the Early Detection of CNS Metastases in Women With Stage IV Breast Cancer N/A